NCT04835883View on ClinicalTrials.gov

Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 26, 2019

Primary Completion Date

November 5, 2021

Study Completion Date

January 20, 2026

Conditions
Systemic Lupus Erythematosus
Interventions
BIOLOGICAL

CS20AT04 (allogenic bone marrow derived mesenchymal stem cell)

Two intravenous infusions of CS20AT04 (2.0×10\^6cell/kg), on 0 day and on 12 weeks The target population of this study is subjects in South Korea with a diagnosis of either lupus nephritis or lupus cytopenia.

Trial Locations (1)

KS013

RECRUITING

Hanyang University Medical Center, Seoul

Sponsors

Collaborators (1)

Corestemchemon, Inc.
All Listed Sponsors
collaborator

Corestemchemon, Inc.

INDUSTRY

collaborator

Ministry of Health & Welfare, Korea

OTHER_GOV

lead

Hanyang University Seoul Hospital

OTHER